Central Sleep Apnea, Mixed Sleep Apnea, Obstructive Sleep Apnea
Conditions
Brief summary
Telemonitoring for Positive Airway Pressure (PAP) therapy might help to establish and maintain long-term therapy adherence and thus support the beneficial effects of PAP therapy on long-term outcomes.
Detailed description
Airway obstructions, airflow resistance by partial occlusion of the airways or central sleep-breathing disorders, where the respiratory effort is reduced or stops, cause a reduction in airflow and lead to arousals from sleep and disturbances in gas exchange during sleep. The negative consequences manifest in increases of blood pressure, higher workload for the heart and daytime sleepiness. PAP (positive airway pressure) treats sleep-related breathing disorders. It applies pressure to nose and mouth to keep the airway from collapsing and provides pressure support to assist the respiratory muscles. The efficacy of the therapy is measured with apnoea- and hypopnoea-indices that count the total number of apnoeic events at night. To ensure an efficacious and efficient therapy, pressures have to be adjusted correctly and the patient needs to use PAP regularly. Telemonitoring is information and communication technology to exchange sleep data and to provide clinical guidance over distances. There is no defined spectrum of technology. It can comprise phone calls, video support or interaction programs via the internet. Some studies point to advantages of telemonitoring in keeping compliance upright, increase usage hours and some also point to economic advantages. However, we do not have conclusive data from large trials with telemonitoring on the long-term that would show conclusive effects, be it from the side of a patient or from a cost and labour perspective of providers or the healthcare sector. Still, there are uncertainties regarding data safety, reimbursement or connectivity of different systems. No long-term data of PAP therapy under telemonitoring and its effect on compliance and therapy outcomes is available by now.
Interventions
Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
Sponsors
ResMed
RWTH Aachen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Inclusion criteria
* Patients older than 18 years * New indication for a prescription of a Telemonitoring (AirViewTM)-capable ResMed PAP-device * Consent to use the telemonitoring System AirViewTM (ResMed GmbH \& Co KG) * Signed Informed Consent
Exclusion criteria
\- Pregnant and breastfeeding persons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Usage Patterns of PAP therapy with telemonitoring, assessed by data continuously recorded by the device and transferred via telemonitoring | 24 months | Usage Patterns are hours/night and nights/month that therapy has been used. Telemonitoring enables the physician to remotely supervise device usage. Usage will be assessed through data recordings of the device: Days of usage \>3hours; Days of usage \<3 hours; total recorded days; mean daily usage (minutes); total usage hours (h) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sleep disorders, assessed by personally questioning the Patient at baseline and at 24 months follow-up | 24 months | Sleep disorders are snoring, insomnia, hypersomnia, depression, restless legs syndrome as assessed by anamnesis. |
| Therapy efficacy, assessed through changes in AHI and HI comparing baseline with 24 months follow-up | 24 months | Efficacy is measured through changes in Apnea-Hypopnea-Index AHI (numbers of apneas - reduction of airflow by \>90% for at least 10 seconds - and hypopneas - reduction of airflow by \>30% for at least 10 seconds with a 4% decrease of Oxygen Saturation - divided by hours of sleep), AI - apnea index (apneas per hour), HI hypopnea index (hypopneas per hour). |
| Quality of Life, assessed with the Functional Outcomes of Sleep Questionnaire (FOSQ) comparing the score at baseline with the 24 months follow-up | 24 months | The Functional Outcomes of Sleep Questionnaire had been developed to comprehensively capture the impact of sleeping disorders in relevant daily activities as for instance general activity, vigilance, intimacy, fitness and social life. |
| Factors leading to therapy Termination, assessed by personally questioning a Patient or Consulting a physician at time of follow-up | 24 months | Possible causes for therapy Termination are assessed: Lost-to-follow-up, no interest in therapy, changed physician, no therapy benefits, Hospital stay, death |
Countries
Germany
Contacts
PRINCIPAL_INVESTIGATORHartmut Grüger, Dr
Grand Arc Düsseldorf
Outcome results
None listed